Peritoneal metastases occur in 55-60% of patients with gastric cancer (GC) and are associated with a 2% 5-year overall survival rate. There are limited treatment options for these patients, and no targeted therapy or immunotherapy is available. Rational therapeutic targets remain to be found. In this review, we present the published literature and our own recent experience in molecular biology to identify important molecules and signaling pathways as well as cellular immunity involved in the peritoneal metastasis of GC. We also suggest potential novel strategies for improving the outcomes of GC patients with peritoneal metastasis.
Keywords: Gastric cancer (GC); epithelial-mesenchymal transition (EMT); immunology; molecular biology; peritoneal carcinomatosis (PC); peritoneal metastases.
2020 Translational Gastroenterology and Hepatology. All rights reserved.